Summary In the present study organotypic multicellular spheroids (OMS) were used to study the effects of chemotherapeutic agents on malignant gliomas. Compared with the frequently used cell line models, OMS have several advantages with respect to the preservation of the cellular heterogeneity and the structure of the original tumour. OMS prepared from seven glioma specimens were treated with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), daunorubicin or doxorubicin. After exposure to these drugs, the histology and cell proliferation of the OMS were analysed by immunohistochemistry and image analysis. Furthermore, the expression of Pglycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated. We found that OMS from gliomas are sensitive for daunorubicin and doxorubicin but not for BCNU in terms of tissue destruction and decrease in cell proliferation. In addition, all gliomas were P-gp and MRP negative, which is in accordance with the sensitivity for daunorubicin and doxorubicin. Considering the potential use of several new alternative drug delivery methods, such as intratumoural implantation of drug-impregnated polymers or liposomal encapsulation of cytostatic drugs, daunorubicin and doxorubicin might be effective in the treatment of malignant gliomas.
Malignant gliomas, accounting for approximately one-half of all primary brain tumours, remain incurable. The mean survival time of patients with a malignant glioma is 8-12 months after standard treatment, consisting of surgical resection and radiotherapy (Lesser and Grossman, 1994) . Most cytostatic drugs are ineffective in the treatment of malignant gliomas. Treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is considered to be the most effective form of chemotherapy in the treatment of gliomas (Edwards et al., 1980; Kornblith and Walker, 1988; Lesser and Grossman, 1994) . However, in controlled, randomised studies no significant differences were found between glioma patients receiving BCNU and radiotherapy vs radiotherapy alone (Walker et al., 1978 (Walker et al., , 1980 Edwards et al., 1980; Kornblith and Walker, 1988; Lesser and Grossman, 1994) . One of the major problems of chemotherapy in the treatment of brain tumours is the limited passage of most drugs through the blood-brain barrier (BBB). Furthermore, several biological mechanisms contribute to resistance to chemotherapeutic agents, such as efficient DNA repair, increased glutathione transferase activity, and overexpression of P-glycoprotein (P-gp) or metallothionein (Deffie et Bradley et al., 1988; Kelley et al., 1988) . Resistance to anthracyclins is often associated with overexpression of P-gp (Bradley et al., 1988) . Furthermore a gene coding for multidrug resistance-related protein MRP has been isolated and has recently also proved to be involved in resistance to daunorubicin and doxorubicin (Cole et al., 1992 (Cole et al., , 1994 .
Preclinical studies on the efficacy of cytostatic drugs for gliomas are usually performed on cell lines or cell line-derived spheroids. Using these culture models it appeared that several drugs that are able to cross the BBB show a high cytolytic activity in vitro, whereas glioma patients respond poorly to these drugs (Yung et al., 1982; Kimmel et al., 1987; Yung 1989) . Lack of cellular heterogeneity in the cell lines used and selection of themosensitive subpopulations during culture are the most likely explanation for this discrepancy (Yung et al., 1982; Kimmel et al., 1987; Westphal et al., 1988; Yung, 1989) .
Surgically removed glioma tissue can be cultured as organotypic multicellular spheroids (OMS), a culture model in which the cellular heterogeneity and other characteristics of the original tumour are preserved (Bjerkvig et al., 1990; Kaaijk et al., 1995) . Therefore, OMS represent the tumour in vivo better than the frequently used cell line models.
In the present study, OMS prepared from malignant gliomas were used to study the effects of daunorubicin and doxorubicin. On the other hand, BCNU was also tested on OMS, because BCNU is considered to be the most promising agent in the treatment of glioma patients. After cytostatic drugs treatment, the OMS were histologically evaluated and cell proliferation was determined. To further analyse the sensitivity for daunorubicin and doxorubicin the expression of P-gp and MRP was examined immunohistochemically. (Scheper et al., 1988) . Furthermore, a monoclonal antibody reacting with the multidrug resistancerelated protein (MRP) was used. Immunostaining for P-gp and MRP was performed on frozen sections of the resection material from the gliomas that had been used for the preparation of the OMS. Paraffin sections (5 Mm) of OMS were placed on organosilan-coated object slides and dried overnight at 37 'C. Sections were deparaffinised and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol. After incubation with monoclonal or polyclonal antibody for 1 h at room temperature, sections were incubated with respectively biotin-conjugated rabbit antimouse immunoglobulins or biotin-conjugated swine antirabbit immunoglobulins (both from Dakopatts). After incubation with streptavidin-biotin complex (Dakopatts), peroxidase activity was developed in 3,3-diamino-benzidinetetrachloride (Sigma) with 0.1% hydrogen peroxide. Sections were counterstained with haematoxylin. Antigen retrieval was necessary for Ki-67 immunostaining and was performed after the endogenous peroxidase blocking step, by incubation in citrate buffer (2.94 gl-' trisodium citrate dihydrate in distilled water; pH6) at 100 'C for 20 min.
Cryostat sections were acetone fixed (5 Mm) and were incubated with the different monoclonal antibodies for 1 h at room temperature. Subsequently, endogenous peroxidase was blocked with 0.3% hydrogen peroxidase in phosphate-buffered saline containing 0.1% sodium azide. Thereafter, sections were incubated with biotin-conjugated rabbit anti-mouse immunoglobulins. After incubation with streptavidin -biotin complex, peroxidase activity was developed in 3-amino-9-ethylcarbazole (Sigma) with 0.1 % hydrogen peroxide. Sections were counterstained with haematoxylin.
Image analysis
The Ki-67 positive nuclei were quantified by computer-based image analysis. Overview Images of OMS immunostained for Ki-67 were acquired with a Sony CCD video camera connected to the standard composite video input port of an Apple Macintosh Quadra 840AV computer. Individual OMS were assessed with image analysis software, using the public domain 'NIH Image' program. A macro was developed that, after background subtraction, counted all immunostained nuclei above a predetermined density value. Subsequently, the number of positive nuclei per mm2 was calculated. The relative cell proliferation in the OMS from each tumour was expressed as a percentage of the untreated control OMS (100%) from that tumour.
Statistics
Statistical analysis of the data was performed using an unpaired two sample t-test; P < 0.03 was considered significant.
Results
Approximately 70-90% of the tumour fragments from the seven gliomas formed OMS. In OMS from all gliomas, with the exception of tumour s52, a dense meshwork of GFAP positive cells and fibrils was observed. In OMS from the oligodendroglioma, s52, oligodendroglial components were present. The presence of capillaries, connective tissue components were common features in the OMS. (Figures lb and 2b) . OMS that were treated with the highest BCNU concentration of 200 pg ml-', showed few histological changes: the glial architecture of the OMS remained intact after treatment, and only a slight increase in cellular necrosis (karyorrhexis with loss of the nuclear membrane and disintegration of the nucleus into clumps of basophilic material) was observed.
In contrast to BCNU, both daunorubicin and doxorubicin induced severe histological damage to the OMS (Figures lc  and d and 2c and d) , even at the lowest concentrations of 2-5 pg ml-'. Applied at the same concentration, daunorubicin was found to be slightly less effective in the induction of tissue damage than doxorubicin. A dose-dependent increase in histological damage could be observed at increasing concentrations of both anthracyclins (Figure 3) . The effects varied from shrinkage of the volume of the OMS, retraction of glial processes (which was clearly visualised with GFAP immunostaining), increased cellular necrosis at the lowest concentrations to almost completely necrotic OMS at higher concentrations with loss of glial architecture, eosinophilic cytoplasm and (micro)vacuolisation in the cytoplasm of the glial tumour cells.
Cell proliferation
The effects of 24 h exposure of cytostatic drugs on cell proliferation in the OMS was analysed 48 h after treatment (Figure 4) . The control OMS of the low-grade astrocytoma (s5 1) showed 1% Ki-67-positive cells, the control OMS of the oligodendroglioma (s52) had 10% Ki-67-positive cells and the control OMS prepared from the glioblastomas (s50, s53, s54, s55, s59) showed a Ki-67 positivity of respectively 3-5%, 2%, 2%, 6-7% and <1%. The number of Ki-67-positive nuclei in OMS from tumour s59 was too low and tumour 59 was excluded from the study of cell proliferation. In all OMS the cells that were Ki-67 positive were apparently vital, none of the Ki-67-positive nuclei were condensed or fragmented.
The relative cell proliferation of all OMS did not change significantly after BCNU exposure in the concentration range of 25-100 pg ml-', with one exception; the proliferation rate in OMS from tumour s55 increased significantly (P<0.03) after treatment with 50 pg ml-' BCNU. The proliferation rates decreased significantly after 200 pg ml-1 BCNU treatment (P<0.03) in OMS from four out of six gliomas. In OMS from tumour s51, s52 and s55 the number of Ki-67-positive tumour cells did not change significantly after 200 pg ml-1 BCNU exposure.
A significant decrease (P<0.03) in number of proliferating cells was seen after incubation with daunorubicin and doxorubicin in all OMS, with the exception of OMS from tumour s55. In OMS from tumour s55, the number of Ki-67-positive tumour cells did not change significantly after exposure to 2, 5, 10 pg ml -' daunorubicin, and 2 pg ml-1 doxorubicin, but a significant decrease of Ki-67-positive tumour cells was seen after exposure to 5 or 10 ,g mldoxorubicin.
P-gp and MRP
In the resection material from all seven gliomas less than 5% of the glial tumour cells were P-gp positive. Some capillaries were positive for P-gp. All seven gliomas were completely MRP negative. spheroids. However, the often described high chemosensitivity of these glioma cell cultures does not correspond to the poor response to chemotherapy seen in glioma patients. Lack of cellular heterogeneity is probably an important factor that contributes to this discrepancy: a cell line represents only a small subpopulation of the original tumour owing to selection during culture (Yung et al., 1982; Kimmel et al., 1987; Wetphal et al., 1988; Yung, 1989) . The effects of cytostatic drugs on an alternative culture model for gliomas, OMS, are described. OMS are more representative of the in vivo situation, because in OMS the original tumour structure, including the cellular heterogeneity, is preserved (Bjerkvig et al., 1990; Kaaijk et al., 1995) .
Similar responses were observed to the various cytostatic drugs for the different glioma types. We found that BCNU induces only minor histological damage to OMS of human gliomas. Even at a concentration of 200 pg ml-' BCNU, which is approximately 100-fold of the maximal achievable pharmacological concentration (Levin et al., 1978) , no obvious histological changes in the OMS were observed. No significant changes in cell proliferation were observed after 2-100 pg ml-' BCNU exposure with the exception of OMS from one tumour that, surprisingly, showed a significant increase in cell proliferation after 50 pg ml-' BCNU treatment. The proliferation marker used in this study recognises the Ki-67 antigen that is assumed to be involved in DNA synthesis. Therefore up-regulation of might also be associated with DNA repair. This could explain the increase in number of Ki-67-positive tumour cells after BCNU treatment in this particular tumour. The proliferation rates in OMS from four out of six gliomas treated with 200 pg ml-' BCNU decreased significantly.
These results are in agreement with other findings in the literature that exposure of organ cultures of malignant astrocytomas to BCNU does not result in microscopic changes (Saez et al., 1977) . Despite the fact that BCNU crosses the BBB, BCNU is ineffective in the treatment of glioma patients (Walker et al., 1978 (Walker et al., , 1980 Edwards et al., 1980; Kornblith and Walker, 1988; Lesser and Grossman, 1994) . Therefore, our results on OMS are in accordance with this poor clinical response to BCNU. However, it is noteworthy that the OMS were examined 48 h after BCNU exposure. It might be that BCNU has more late effects rather than acute effects on glioma tissue. In contrast to BCNU, daunorubicin and doxorubicin induce severe tissue damage and a significant decrease in cell proliferation, already found at the lowest concentrations tested of 2-5 pg ml'-. Clinical trials, however, revealed a poor response of glioma patients to doxorubicin. In one of these studies it was shown that doxorubicin did not reach cytotoxic levels in the glioma tissue, owing to delivery problems (von Holst et al., 1990) . This explains the lack of therapeutic response in these studies.
Overexpression of P-gp on tumour cells in vitro may lead to resistance to a broad spectrum of unrelated cytostatic drugs, including anthracyclins (Bradley et al., 1988) . It has been reported that glioma cells in situ hardly ever express Pgp (Tanaka et al., 1994) , which is in agreement with our findings. In addition, we showed that all seven gliomas were negative for MRP, which has also been found to be associated with resistance to daunorubicin and doxorubicin (Cole et al., 1994) . Thus glioma cells may be sensitive for daunorubicin and doxorubicin. The limited passage of doxorubicin through the BBB might be an explanation for the ineffectiveness of doxorubicin in glioma patients.
The present study shows that daunorubicin and doxorubicin may be potent drugs for treating malignant gliomas, when tumoricidal concentrations can be reached. This can be accomplished by intratumoural administration of the drugs or intratumoural implantation of drug-impregnated polymers (Brem et al., 1991) . Liposomal encapsulation of cytostatic drugs is another alternative to circumvent the limited BBB passage. Liposomal encapsulation of anthracyclins reduces side-effects, and increases the delivery of the drugs to solid tumours (Forssen et al., 1992) . Besides this, new derivates of daunorubicin have become available, which are more lipophilic and more potent in killing glioma cells (Schott et al., 1989) .
In conventional in vitro drug testing assays with cell lines, cell killing (as in radiolabelled precursor inhibition assays or microcytotoxicty assays) or cell proliferation inhibition (as in colony-forming assays) is measured (Kimmel et al., 1987) . In contrast, in OMS the histological cytotoxic effects of cytostatic drugs, as well as the inhibition of cell proliferation, can be studied in one sample. Exposure of OMS to cytostatic drugs appeared to be a reliable and simple method. Hence, OMS are useful as a predictive test model for individual patient's responses to several cytostatic drugs and might have importance in screening new chemotherapeutic agents for future clinical trials.
